European Journal of Pharmaceutics and Biopharmaceutics
Journal Information
ISSN / EISSN :
0939-6411 / 1873-3441
Current Publisher: Elsevier BV (10.1016)
Former Publisher:
Elsevier BV (10.116)
Total articles ≅ 5,457
Current Coverage
SCOPUS
PUBMED
MEDLINE
MEDICUS
SCIE
Archived in
SHERPA/ROMEO
EBSCO
Filter:
Latest articles in this journal
European Journal of Pharmaceutics and Biopharmaceutics; doi:10.1016/j.ejpb.2021.03.015
Abstract:
In the pharmaceutical industry, cryoprotectants are added to buffer formulations to protect the active pharmaceutical ingredient from freeze- and thaw damage. We investigated the freezing and thawing of aqueous sodium citrate buffer with various cryoprotectants, specifically amino acids (cysteine, histidine, arginine, proline and lysine), disaccharides (trehalose and sucrose), polyhydric alcohols (glycerol and mannitol) and surfactants (polysorbate 20 and polysorbate 80). Hereby, we employed optical cryomicroscopy in combination with differential scanning calorimetry in the temperature range to -80°C. The effect of cryoprotectants on the morphology of the ice crystals, the glass transition temperature and the initial melting temperature is presented. Some of the cryoprotectants have a significant impact on ice crystal size. Disaccharides restrict ice crystal growth, whereas surfactants and glycerol allow ice crystals to increase in size. Cysteine and mannitol cause dehydration after thawing. Either one or two glass transition temperatures were detected, where arginine, surfactants, glycerol, proline and lysine suppress the second, implying a uniform freeze-concentrated solution. The initial melting temperature of pure buffer solution can be shifted up by adding mannitol, both disaccharides and both surfactants; but down by glycerol, proline and lysine.
European Journal of Pharmaceutics and Biopharmaceutics, Volume 161, pp 4-14; doi:10.1016/j.ejpb.2021.02.002
The publisher has not yet granted permission to display this abstract.
European Journal of Pharmaceutics and Biopharmaceutics, Volume 161, pp 80-99; doi:10.1016/j.ejpb.2021.02.007
The publisher has not yet granted permission to display this abstract.
European Journal of Pharmaceutics and Biopharmaceutics; doi:10.1016/j.ejpb.2021.03.014
The publisher has not yet granted permission to display this abstract.
European Journal of Pharmaceutics and Biopharmaceutics, Volume 161, pp 56-65; doi:10.1016/j.ejpb.2021.02.005
The publisher has not yet granted permission to display this abstract.
European Journal of Pharmaceutics and Biopharmaceutics, Volume 161, pp 100-119; doi:10.1016/j.ejpb.2021.02.010
The publisher has not yet granted permission to display this abstract.
European Journal of Pharmaceutics and Biopharmaceutics, Volume 161, pp 29-36; doi:10.1016/j.ejpb.2021.02.001
The publisher has not yet granted permission to display this abstract.
European Journal of Pharmaceutics and Biopharmaceutics, Volume 161; doi:10.1016/s0939-6411(21)00063-1
European Journal of Pharmaceutics and Biopharmaceutics, Volume 161, pp 37-49; doi:10.1016/j.ejpb.2021.01.014
The publisher has not yet granted permission to display this abstract.
European Journal of Pharmaceutics and Biopharmaceutics; doi:10.1016/j.ejpb.2021.03.016
The publisher has not yet granted permission to display this abstract.